Latest research and treatment of advanced-stage epithelial ovarian cancer

Abstract

The natural history of ovarian cancer continues to be characterized by late-stage presentation, metastatic bulky disease burden and stagnant mortality statistics despite prolific drug development. Robust clinical investigation, particularly with modifications to primary treatment surgical goals and adjuvant therapy are increasing median progression-free and overall survival, although the cure rates have only modestly been affected. Maintenance therapy holds promise, but studies have yet to identify an agent and/or strategy that can affect survival. Recurrent disease is largely an incurable state; however, current intervention with selected surgery, combination and targeted therapy and investigational protocols are impacting progression-free survival. Ovarian cancer is a diverse and genomically complex disease, which commands global attention. Rational investigation must balance the high rate of discovery with lagging clinical investigation and limited patient resources. Nevertheless, armamentarium growth offers unprecedented opportunities for patients suffering with this disease. This Review presents and reviews the contemporary management of the disease spectrum termed epithelial ‘ovarian’ cancer and introduces the direction and early results of clinical investigation.

Selective targeting of metastatic ovarian cancer using an engineered anthrax prodrug activated by membrane-anchored serine proteases

“…Tumor foci were distributed adjacent to the spleen, liver, kidneys, and intestinal tract. Disease presentation in this model is consistent with disease presentation in OvCa patients ( 35 ). In contrast, PAS:LF–treated mice did not present with ascites fluid accumulation or widespread tumor foci throughout the peritoneal cavity ( Fig.…”

Selective targeting of metastatic ovarian cancer using an engineered anthrax prodrug activated by membrane-anchored serine proteases

“…Tumor foci were distributed adjacent to the spleen, liver, kidneys, and intestinal tract. Disease presentation in this model is consistent with disease presentation in OvCa patients ( 35 ). In contrast, PAS:LF–treated mice did not present with ascites fluid accumulation or widespread tumor foci throughout the peritoneal cavity ( Fig.…”

What are the Barriers and Enablers to Physical Activity Participation in Women with Ovarian Cancer? A Rapid Review of the Literature

“…15 This is unsurprising, given the higher treatment and disease burden associated with advanced stage ovarian cancer. 35 A small proportion of women with ovarian cancer reported cost as a barrier, 15 consistent with findings in gynaecological cancer survivors. 20 Other barriers which were unique to ovarian cancer included lack of routine, procrastination and significant life events, 14,15 although no further detail were reported as these findings were obtained from questionnaires.…”

Cytoreduction surgery with hyperthermic intraperitoneal chemotherapy in recurrent ovarian cancer improves progression‐free survival, especially in BRCA‐positive patients—A case‐control study

“…Treatment of rEOC with chemotherapy alone usually results in a median OS of around 30 months . It is noteworthy that in the current study, the control group that received systemic chemotherapy alone had an impressive median OS of 58.4 months.…”

Selective targeting of metastatic ovarian cancer using an engineered anthrax prodrug activated by membrane-anchored serine proteases

“…Tumor foci were distributed adjacent to the spleen, liver, kidneys, and intestinal tract. Disease presentation in this model is consistent with disease presentation in OvCa patients ( 35 ). In contrast, PAS:LF–treated mice did not present with ascites fluid accumulation or widespread tumor foci throughout the peritoneal cavity ( Fig.…”

What are the Barriers and Enablers to Physical Activity Participation in Women with Ovarian Cancer? A Rapid Review of the Literature

“…15 This is unsurprising, given the higher treatment and disease burden associated with advanced stage ovarian cancer. 35 A small proportion of women with ovarian cancer reported cost as a barrier, 15 consistent with findings in gynaecological cancer survivors. 20 Other barriers which were unique to ovarian cancer included lack of routine, procrastination and significant life events, 14,15 although no further detail were reported as these findings were obtained from questionnaires.…”

Cytoreduction surgery with hyperthermic intraperitoneal chemotherapy in recurrent ovarian cancer improves progression‐free survival, especially in BRCA‐positive patients—A case‐control study

“…Treatment of rEOC with chemotherapy alone usually results in a median OS of around 30 months . It is noteworthy that in the current study, the control group that received systemic chemotherapy alone had an impressive median OS of 58.4 months.…”

Selective targeting of metastatic ovarian cancer using an engineered anthrax prodrug activated by membrane-anchored serine proteases

“…Tumor foci were distributed adjacent to the spleen, liver, kidneys, and intestinal tract. Disease presentation in this model is consistent with disease presentation in OvCa patients ( 35 ). In contrast, PAS:LF–treated mice did not present with ascites fluid accumulation or widespread tumor foci throughout the peritoneal cavity ( Fig.…”

What are the Barriers and Enablers to Physical Activity Participation in Women with Ovarian Cancer? A Rapid Review of the Literature

“…15 This is unsurprising, given the higher treatment and disease burden associated with advanced stage ovarian cancer. 35 A small proportion of women with ovarian cancer reported cost as a barrier, 15 consistent with findings in gynaecological cancer survivors. 20 Other barriers which were unique to ovarian cancer included lack of routine, procrastination and significant life events, 14,15 although no further detail were reported as these findings were obtained from questionnaires.…”

Cytoreduction surgery with hyperthermic intraperitoneal chemotherapy in recurrent ovarian cancer improves progression‐free survival, especially in BRCA‐positive patients—A case‐control study

“…Treatment of rEOC with chemotherapy alone usually results in a median OS of around 30 months . It is noteworthy that in the current study, the control group that received systemic chemotherapy alone had an impressive median OS of 58.4 months.…”